HAYA Therapeutics Establishes U.S. Location

- - HAYA closes US$5M seed extension led by Humboldt Fund to advance the development of its anti-fibrotic lead program targeting Wisper, a cardiac long non-coding RNA
  LAUSANNE, Switzerland & SAN DIEGO–(BUSINESS WIRE)–HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), today announced that the company has established a new laboratory space at JLABS @ San Diego, part of Johnson & Johnson Innovation’s global network of life science incubators